Key Highlights
- Federal guidance allowing states to postpone enforcement of Medicaid work requirements through June 30, 2027, sent Molina Healthcare (NYSE:MOH) up 11.27% on November 16, 2026.
- Summit Therapeutics plunged 16.47% after the FDA sent a complete response letter on ivonescimab in EGFR-mutated lung cancer, pointing to the absence of a significant overall survival benefit.
- Novartis announced on November 17 that the FDA had approved Cosentyx 150 mg in polymyalgia rheumatica, its 11th US indication, while an upgrade took Humana up 2.50% to a 52-week high.
- After hours on November 16, Omeros dropped about 10.4% as YARTEMLEA net Revenue of USD 35.9 million, up 26% on the prior quarter, disappointed.
1. Molina Healthcare (NYSE:MOH)
The largest gain among big managed care companies on November 16 went to Molina Healthcare (NYSE:MOH), up 11.27% while the S&P 500 fell 1.92%. Guidance from the Centers for Medicare and Medicaid Services was the catalyst: it gives states an optional hold harmless period on the work and community engagement requirements created by the 2025 budget reconciliation law, which were set to begin on January 1, 2027. Enforcement can be postponed by states for as long as six months, through June 30, 2027. They still have to verify whether enrollees meet the rules in that window, but they can hold off on ending coverage for otherwise eligible people who have not yet shown compliance. As the most Medicaid-focused of the large insurers, Molina benefits from fewer disenrollments in early 2027, which mean more members and less disruption to medical cost trends, since healthier people tend to drop off first. On the same news Centene gained 4.91% and Elevance Health 3.86%. Take-up determines the benefit. By December 11, 2026, states must tell the federal government whether they will use the delay, and because the requirements are postponed and not removed, the enrollment impact may move into the second half of 2027. Next markers are state rate updates for 2027 and company membership assumptions.
2. Summit Therapeutics (NASDAQ:SMMT)
On November 15 Summit Therapeutics (NASDAQ:SMMT) disclosed that the FDA had issued a complete response letter on its ivonescimab application, and the shares fell 16.47%. Approval was sought for use with platinum chemotherapy in advanced non-small cell lung cancer that progressed after EGFR inhibitor therapy, on the strength of the HARMONi trial. Progression-free survival, the primary endpoint, was met, while overall survival trended positively without reaching statistical significance. A progression-free benefit with no significant survival benefit, the FDA said, does not support a positive benefit-risk profile in this setting. Summit cited a post-hoc longer follow-up with a hazard ratio of 0.76, consistent across Asian and western patients, although regulators give post-hoc analyses less weight. On safety, treatment-related side effects led 7.3% of patients to stop ivonescimab versus 5.0% on the control arm. Much of the valuation rests on the drug, which Summit licensed from Akeso for major markets, so the rejection pushes the earliest US approval further out and underlines how much survival data matter in lung cancer. HARMONi-3 in first-line lung cancer and HARMONi-7 in patients with high PD-L1 expression now draw the attention. Conviction is unchanged, Summit said, and several Phase 3 trials are continuing.
3. Novartis (NYSE:NVS)
An established drug gained a new market at Novartis (NYSE:NVS). On November 17 the company said the FDA had approved Cosentyx 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a steroid taper. As the first anti-IL-17 biologic approved for the disease, it marks the drug's 11th US indication. Pain and stiffness in the shoulders, neck and hips, mainly in people over 50, characterise the condition, which about 966,000 people in the United States have, with up to 40% relapsing in the first year. Steroids have been the mainstay of treatment, and long-term use carries risks such as bone loss, diabetes and infection. In the Phase III REPLENISH trial, conducted in 27 countries, Cosentyx doubled the likelihood of sustained remission as patients tapered off steroids. Approval already exists in the European Union, and Japan has a review under way. Rheumatologists' willingness to switch patients from inexpensive steroids to a costly biologic, insurer rules that may Demand steroid failure first, and competition from an IL-6 inhibitor already approved in the disease will determine uptake. Because biosimilar versions of Cosentyx are expected later in the decade, the long-term value of each new label is limited.
4. Humana (NYSE:HUM)
A major broker upgraded Humana (NYSE:HUM) to Outperform from Sector Perform and raised its price target to USD 563 from USD 415, and on November 16 the shares gained 2.50% and touched a 52-week high near USD 459.53. Growing confidence that Margin recovery in Medicare Advantage is on track lies behind the call. For two years insurers in that market absorbed higher medical utilisation, tighter government payment rates and lower quality-rating bonuses. Lately, 2027 payment rates have come in better than feared, plans have been repriced and insurers have left unprofitable counties. With a heavier concentration in Medicare Advantage than its diversified peers, Humana has the most Leverage to a recovery. On the day, health care held up better than most, slipping 0.51% against a 3.24% drop for technology, and the Medicaid policy news lifted the wider managed care group. Risks persist: medical cost trends are elevated, regulators keep scrutinising risk adjustment and quality ratings, and enrolment results from the annual election period, running through early December, will show whether benefit and pricing changes preserved membership. Initial 2027 guidance, normally given early in the new year, is the clearest test, and the quick move leaves less room should cost trends turn up again.
5. Omeros (NASDAQ:OMER)
Sales of YARTEMLEA, Omeros's narsoplimab treatment for transplant-associated thrombotic microangiopathy, kept growing, yet Omeros (NASDAQ:OMER) dropped about 10.4% after hours on November 16. Gross sales for the third quarter reached USD 41.8 million, 30% above the second quarter, and net revenue climbed 26% to USD 35.9 million, but that fell short of investor expectations. Regulation shapes upside and risk alike. Hospital adoption should be helped by a new Medicare technology add-on payment, effective October 1 and worth up to USD 287,079 per eligible inpatient case. Europe is different: after re-examining an earlier negative view, the medicines committee issued a negative opinion in October 2026, confining the near-term market to the United States. A USD 62.0 million non-cash loss on the derivative in its 2029 convertible notes drove the GAAP net loss of USD 57.4 million, or USD 0.79 per share, whereas adjusted Net Income was USD 4.7 million and Operating Cash Flow USD 13.3 million. The company holds USD 95.3 million in cash and short-term investments and expects near-term milestone payments of up to USD 100 million from an earlier asset sale. Fourth quarter sales, which the Medicare payment should help, are the next test.
Where Things Stand
Novartis has the clearest path among the top 5 healthcare stocks moved by regulators and policy, with a new label in a large patient group and approvals already in Europe. Molina hinges on how many states adopt the Medicaid delay by December 11, Humana on Medicare Advantage margins, Omeros on US adoption following a negative European opinion, and Summit on survival data from its next Phase 3 trials.



![Arch Biopartners Inc. Turns Heads as Phase II kidney-drug development Sparks New Trading Interest on the TSXV Composite — Small Cap Growth Stock [TSXV:ARCH]](/featured_image/gallery/medium/shutterstock_2606085317_11_18_2026_16_10_43_645635.jpg)
![Vimy Pharmaceuticals Corp. Momentum Jumps as its new-listing debut Puts the TSXV Composite in Focus — Small Cap-Growth Stock [TSXV:VIMY]](/featured_image/gallery/medium/shutterstock_512538715_11_18_2026_16_11_17_989273.jpg)
![WELLSTAR Technologies Corp. Momentum Jumps as record public-company quarterly growth Puts the TSXV Composite in Focus — Small Cap-Growth Stock [TSXV:WSTR]](/featured_image/gallery/medium/shutterstock_2439951387_11_18_2026_16_11_37_467341.jpg)
Please wait processing your request...